Laurence Kraus‐Berthier

2.0k citations

50 papers · 1.4k indexed · h-index 24

Toxicology top 1%
- Bioactive Compounds and Antitumor Agents 10
Organic Chemistry top 5%
- Synthesis and biological activity 4
Cancer Research top 10%
- Synthesis and Biological Activity 4
Molecular Biology top 10%
- Cancer therapeutics and mechanisms 27
- Histone Deacetylase Inhibitors Research 7
- Phytochemical compounds biological activities 3
Oncology top 10%
- Drug Transport and Resistance Mechanisms 6
Plant Science
- Plant chemical constituents analysis 6

Co-authors: Stéphane Léonce Alain St. Pierre Ghanem Atassi Nicolas Guilbaud Sylvie Michel Bruno Pfeiffer Michel Koch Pierre Renard
Cited by: Toxicology Organic Chemistry Cancer Research
Journals: Blood (1 paper)PLoS ONE (2 papers)Cancer Research (2 papers)
Partner nations: France Belgium Australia

In The Last Decade

Laurence Kraus‐Berthier

50 papers receiving 1.3k citations

Peers

Countries citing papers authored by Laurence Kraus‐Berthier

Since Specialization

Citations

This map shows the geographic impact of Laurence Kraus‐Berthier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Kraus‐Berthier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Kraus‐Berthier more than expected).

Fields of papers citing papers by Laurence Kraus‐Berthier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Kraus‐Berthier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Kraus‐Berthier. The network helps show where Laurence Kraus‐Berthier may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Laurence Kraus‐Berthier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Laurence Kraus‐Berthier Line = papers co-authored together Laurence Kraus‐Berthier links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation Investigational New Drugs ·Philippe B. Pierrillas,Émilie Hénin,Julien Ogier,Magali Amiel,Laurence Kraus‐Berthier,Marylore Chenel,François Bouzom,Michel Tod	2020	2
2	Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma Haematologica ·Esperanza M. Algarín,Andrea Díaz-Tejedor,Pedro Mogollón,Susana Hernández-García,Luís A. Corchete,Laura San‐Segundo,Montserrat Martín-Sánchez,Lorena González-Méndez,Marie Schoumacher,Sébastien Banquet,Laurence Kraus‐Berthier,Ioana Kloos,Alix Derréal,Ensar Halilovic,Heiko Maacke,Norma C. Gutiérrez,María‐Victoria Mateos,Teresa Paíno,Mercedes Garayoa,Enrique M. Ocio	2019	42
3	Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy Drug Metabolism and Disposition ·Philippe B. Pierrillas,Émilie Hénin,Kathryn Ball,Julien Ogier,Magali Amiel,Laurence Kraus‐Berthier,Marylore Chenel,François Bouzom,Michel Tod	2019	8
4	Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity In AML Experimental Hematology ·Jessica M. Salmon,Giovanna Pomilio,Donia M. Moujalled,Sarah MacRaild,Charis E. Teh,Sewa Rijal,Adam Ivey,Tse-Chieh Teh,Paul G. Ekert,Marie Schoumacher,Laurence Kraus‐Berthier,Ioana Kloos,Daniel H.D. Gray,Andrew H. Wei	2018	2
5	Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice Journal of Pharmacology and Experimental Therapeutics ·Philippe B. Pierrillas,Émilie Hénin,Julien Ogier,Laurence Kraus‐Berthier,Marylore Chenel,François Bouzom,Michel Tod	2018	3
6	Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma Gene ·Diana Markozashvili,Andrey Pichugin,Ana Barat,Valérie Camara‐Clayette,N. V. Vasilyeva,Hélène Lelièvre,Laurence Kraus‐Berthier,Stéphane Depil,Vincent Ribrag,Yegor Vassetzky	2016	6
7	Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts PLoS ONE ·Fariba Némati,Catherine de Montrion,Guillaume Lang,Laurence Kraus‐Berthier,Guillaume Carita,Xavier Sastre‐Garau,Aurélie Berniard,David Vallerand,Olivier Geneste,Ludmilla de Plater,Alain St. Pierre,Brian Lockhart,Laurence Desjardins,Sophie Piperno‐Neumann,Stéphane Depil,Didier Decaudin	2014	37
8	The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression Clinical Cancer Research ·Marion A. Salvador,Julien Wicinski,Olivier Cabaud,Yves Toiron,Pascal Finetti,Emmanuelle Josselin,Hélène Lelièvre,Laurence Kraus‐Berthier,Stéphane Depil,François Bertucci,Yves Collette,Daniel Birnbaum,Emmanuelle Charafe‐Jauffret,Christophe Ginestier	2013	113
9	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms Cell Death and Disease ·Ashfaq Ali,Olivier Bluteau,Kahia Messaoudi,Alberta Palazzo,Siham Boukour,Larissa Lordier,Yann Lécluse,Philippe Rameau,Laurence Kraus‐Berthier,Anne Jacquet-Bescond,Hervé Lelièvre,Stéphane Depil,Philippe Dessen,Éric Solary,Hana Raslová,William Vainchenker,Isabelle Plo,Najet Debili	2013	28
10	Influence of the Stereoisomeric Position of the Reactive Acetate Groups of the Benzo[b]Acronycine derivative S23906-1 on Its DNA Alkylation, Helix-Opening, Cytotoxic, and Antitumor Activities Molecular Pharmacology ·Sabine Depauw,Thomas Gaslonde,Stéphane Léonce,Laurence Kraus‐Berthier,William Laine,Gaëlle Lenglet,A. Chiaroni,Bruno Pfeiffer,Christian Bailly,Sylvie Michel,François Tillequin,Alain St. Pierre,Marie‐Hélène David‐Cordonnier	2009	8
11	Novel Stable Camptothecin Derivatives Replacing the E-Ring Lactone by a Ketone Function Are Potent Inhibitors of Topoisomerase I and Promising Antitumor Drugs Molecular Pharmacology ·Amélie Lansiaux,Stéphane Léonce,Laurence Kraus‐Berthier,Christine Bal-Mahieu,Romain Mazinghien,Sébastien Didier,Marie‐Hélène David‐Cordonnier,Patrick Hautefaye,Gilbert Lavielle,Christian Bailly,John A. Hickman,Alain St. Pierre	2007	25
12	Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues Bioorganic & Medicinal Chemistry ·Claude Guillonneau,Annette Nault,Eric Raimbaud,Stéphane Léonce,Laurence Kraus‐Berthier,Alain St. Pierre,Solo Goldstein	2004	22
13	Antitumor activity of S 16020-2 in two orthotopic models of lung cancer Anti-Cancer Drugs ·Nicolas Guilbaud,Laurence Kraus‐Berthier,Dominique Saint-Dizier,M. -H. Rouillon,Musamey Jan,Mike F. Burbridge,Alain Pierr�,Ghanem Atassi	1997	16
14	Experimental Antitumour Activity of S 16020-2 in a Panel of Human Tumours European Journal of Cancer ·Laurence Kraus‐Berthier,Nicolas Guilbaud,M. Jan,Dominique Saint-Dizier,M. -H. Rouillon,Mike F. Burbridge,Alain Pierré,Ghanem Atassi	1997	14
15	Synthesis and Biological Evaluation of 6-(9-Hydroxy-5-methyl(and 5,6-Dimethyl)-6H-pyrido(4,3-b)carbazol-1-yl)picolinic Amides as New Olivacine Derivatives. Chemical and Pharmaceutical Bulletin ·C. LANDRAS,R. Jasztold-Howorko,Alain St. Pierre,Stéphane Léonce,Nicolas Guilbaud,Laurence Kraus‐Berthier,Claude Guillonneau,Yves Rolland,Ghanem Atassi,Émile Bisagni	1996	5
16	In vivo antitumor activity of S 16020-2, a new olivacine derivative Cancer Chemotherapy and Pharmacology ·Nicolas Guilbaud,Laurence Kraus‐Berthier,Dominique Saint-Dizier,M. -H. Rouillon,M. Jan,Mike F. Burbridge,M. Visalli,Émile Bisagni,Pierre Alexandre Eric Djifaby Sombié,Ghanem Atassi	1996	23
17	Synthesis and Evaluation of 9-Hydroxy-5-methyl- (and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazole-1-N-[(dialkylamino)alkyl]carboxamides, a New Promising Series of Antitumor Olivacine Derivatives Journal of Medicinal Chemistry ·R. Jasztold-Howorko,C. LANDRAS,Pierre Alexandre Eric Djifaby Sombié,Ghanem Atassi,Nicolas Guilbaud,Laurence Kraus‐Berthier,Stéphane Léonce,Yves Rolland,Jacques Prost,Émile Bisagni	1994	33
18	In vivo immunopharmacological properties of tuftsin and four analogs Immunopharmacology ·Laurence Kraus‐Berthier,G. REMOND,M. Visalli,Danièle Héno,Bernard Portevin,Michel Vincent	1993	3
19	New triazine derivatives as potent modulators of multidrug resistance Journal of Medicinal Chemistry ·Alain Dhainaut,G Régnier,Ghanem Atassi,Alain St. Pierre,Stéphane Léonce,Laurence Kraus‐Berthier,Jean François Prost	1992	58
20	Approaches to some biochemical mechanisms of action of tuftsin and analogues Biochemical Pharmacology ·Laurence Kraus‐Berthier,Gilles Ferry,Valérie Combe-Perez,M. Visalli,G. REMOND,M. Vincent,Jean A. Boutin	1991	7

About Laurence Kraus‐Berthier

Laurence Kraus‐Berthier is a scholar working on Toxicology, Oncology and Molecular Biology, having authored 50 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (27 papers), Bioactive Compounds and Antitumor Agents (10 papers), Histone Deacetylase Inhibitors Research (7 papers), Plant chemical constituents analysis (6 papers), Drug Transport and Resistance Mechanisms (6 papers), Synthesis and biological activity (4 papers), Synthesis and Biological Activity (4 papers) and Phytochemical compounds biological activities (3 papers). The work is most often cited by research in Toxicology (153 citations), Organic Chemistry (531 citations) and Cancer Research (209 citations). Laurence Kraus‐Berthier has collaborated with scholars based in France, Belgium and Australia. Frequent co-authors include Stéphane Léonce, Alain St. Pierre, Ghanem Atassi, Nicolas Guilbaud, Sylvie Michel, Bruno Pfeiffer, Michel Koch, Pierre Renard, François Tillequin and Stéphane Depil. Their work appears in journals such as Blood, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact